You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 25, 2024

Claims for Patent: 8,461,101

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,461,101

Title:	Targeting PAX2 for the treatment of breast cancer
Abstract:	The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject.
Inventor(s):	Donald; Carlton D. (Mount Pleasant, SC)
Assignee:	Phigenix, Inc. (Atlanata, GA)
Application Number:	13/114,824
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,461,101
Patent Claims:	1. A method for treating a breast condition in a subject, comprising: (a) determining the PAX2-to-DEFB1 expression ratio in a diseased breast tissue from said subject; (b) determining the ER/PR status of said diseased breast tissue from said subject; and (c) based on the results of (a) and (b), administering to the subject, an effective amount of a composition that inhibits PAX2 expression and/or PAX2 activity, wherein said composition comprises a RAS signaling pathway blocker. 2. The method of claim 1, wherein said breast condition is breast cancer or MIN. 3. The method of claim 1, wherein said first composition is an anti-PAX2 agent conjugated to an antibody, a receptor or a ligand to target tumor tissue in said subject. 4. The method of claim 1, wherein the step (c) further comprises administering a second composition comprising an anti-hormonal agent. 5. The method of claim 4, wherein the anti-hormonal agent is Tamoxifen. 6. The method of claim 1, wherein the step (c) further comprises administering a second composition comprising an anti-ERBB-2/anti-Her-2 agent. 7. The method of claim 6, wherein the anti-ERBB-2/anti-Her-2 agent is trastuzumab. 8. The method of claim 1, wherein the step (c) further comprises administering a second composition comprising an anti-AIB-1/SRC-3 agent.

Details for Patent 8,461,101

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998	⤷ Try a Trial	2025-10-14
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017	⤷ Try a Trial	2025-10-14
Genentech, Inc.	HERCEPTIN HYLECTA	trastuzumab and hyaluronidase-oysk	Injection	761106	02/28/2019	⤷ Try a Trial	2025-10-14
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.